Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
“For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (98,99).”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Clinical pancreatic islet transplantation
Shapiro, A. M. J., Pokrywczynska, M., & Ricordi, C. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.178 · Cited by 747
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
“For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (56,57).”
Background6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Advances in islet encapsulation technologies
Desai, T., & Shea, L. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.232 · Cited by 427
Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells
Velazco-Cruz, L., Song, J., Maxwell, K. G., Goedegebuure, M. M., Augsornworawat, P., Hogrebe, N. J., & Millman, J. R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.012 · Cited by 399
“An alternative treatment is replacement of the endogenous b cells by transplantation of pancreatic islets (Bellin et al., 2012; Hering et al., 2016; Lacy and Kostianovsky, 1967; Scharp et al., 1990; Shapiro et al., 2000).”
BackgroundZhou, Q., & Melton, D. A. (2018) · Nature · doi:10.1038/s41586-018-0088-0 · Cited by 385
Bioprinting: From Tissue and Organ Development to in Vitro Models
Mota, C., Camarero-Espinosa, S., Baker, M. B., Wieringa, P., & Moroni, L. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00789 · Cited by 345
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342
Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
Rickels, M. R., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00154 · Cited by 329
Self-citationShapiro, A. M. J., Thompson, D., Donner, T. W., Bellin, M. D., Hsueh, W., Pettus, J., Wilensky, J., Daniels, M., Wang, R. M., Brandon, E. P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100466 · Cited by 313
Self-citationSackett, S. D., Tremmel, D. M., Ma, F., Feeney, A. K., Maguire, R. M., Brown, M. E., Zhou, Y., Li, X., O’Brien, C., Li, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28857-1 · Cited by 269
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“Contrarily, pancreatic islet cell transplantation for the treatment of insulin-deficient diabetes and pancreatitis has shown more promising potential (120), with clinical outcomes being dependent on islet availability and engraftment success rates, and limited with non-specific inflammatory/thrombotic mechanisms post-…”
BackgroundStem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges
Sneddon, J. B., Tang, Q., Stock, P., Bluestone, J. A., Roy, S., Desai, T., & Hebrok, M. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.016 · Cited by 250
Self-citationPancreatic β Cell Regeneration as a Possible Therapy for Diabetes
Aguayo-Mazzucato, C., & Bonner-Weir, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.007 · Cited by 237
Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 154
Carlsson, P.-O., Espes, D., Sedigh, A., Rotem, A., Zimerman, B., Grinberg, H., Goldman, T., Barkai, U., Avni, Y., Westermark, G. T., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14642 · Cited by 205
“22-24 The problems encountered could be attributed to (1) the significant contribution of glucose effectiveness for glucose metabolism in small animals,25 (2) limited islet survival due to diffusion problems of oxygen and nutrients occurring when the device has been upscaled from harboring a few hundred islets to enco…”
Self-citationAdvances in β-cell replacement therapy for the treatment of type 1 diabetes
Vantyghem, M.-C., de Koning, E. J. P., Pattou, F., & Rickels, M. R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31334-0 · Cited by 201
Self-citationLablanche, S., Vantyghem, M.-C., Kessler, L., Wojtusciszyn, A., Borot, S., Thivolet, C., Girerd, S., Bosco, D., Bosson, J.-L., Colin, C., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30078-0 · Cited by 200
Ricordi, C., Goldstein, J. S., Balamurugan, A. N., Szot, G. L., Kin, T., Liu, C., Czarniecki, C. W., Barbaro, B., Bridges, N. D., Cano, J., et al. (2016) · Diabetes · doi:10.2337/db16-0234 · Cited by 196
Self-citationInadequate β-cell mass is essential for the pathogenesis of type 2 diabetes
Weir, G. C., Gaglia, J., & Bonner-Weir, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30022-x · Cited by 194
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 152
Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
Reichman, T. W., Markmann, J. F., Odorico, J., Witkowski, P., Fung, J. J., Wijkstrom, M., Kandeel, F., de Koning, E. J. P., Peters, A. L., Mathieu, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2506549 · Cited by 177
Self-citation6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Keymeulen, B., Groot, K. D., Jacobs‐Tulleneers‐Thevissen, D., Thompson, D. M., Bellin, M. D., KROON, E. J., Daniels, M., Wang, R. M., JAIMAN, M. S., Kieffer, T. J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-02055-5 · Cited by 165
Self-citationJiang, K., Weaver, J. D., Li, Y., Chen, X., Liang, J., & Stabler, C. L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.004 · Cited by 162
Bioengineering of an Intraabdominal Endocrine Pancreas
Baidal, D. A., Ricordi, C., Berman, D. M., Alvarez, A., Padilla, N., Ciancio, G., Linetsky, E., Pileggi, A., & Alejandro, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1613959 · Cited by 160
Self-citationStem Cell-Based Clinical Trials for Diabetes Mellitus
de Klerk, E., & Hebrok, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.631463 · Cited by 156
PDX1 is the cornerstone of pancreatic β-cell functions and identity
Ebrahim, N., Shakirova, K. S., & Dashinimaev, E. B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1091757 · Cited by 152
“Many approaches are being used in the treatment of diabetes, ranging from conventional methods, like the use of pharmaceutical compounds, to more advanced approaches such as gene and cellular therapies (Ryan et al., 2005; Wong et al., 2010; Sorli and Heile, 2014; Hering et al., 2016; Loretelli et al., 2020).”
MethodStem cells in the treatment of diabetes mellitus — Focus on mesenchymal stem cells
Päth, G., Perakakis, N., Mantzoros, C. S., & Seufert, J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.10.005 · Cited by 142
Foster, E. D., Bridges, N. D., Feurer, I. D., Eggerman, T. L., Hunsicker, L. G., Alejandro, R., Clinical Islet Transplantation Consortium, Begley, B., Cano, J., Carpentier, S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1779 · Cited by 119
Self-citationLatres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 117
Advances in Pancreatic Islet Transplantation Sites for the Treatment of Diabetes
Cayabyab, F., Nih, L. R., & Yoshihara, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.732431 · Cited by 134
Engineering islets from stem cells for advanced therapies of diabetes
Siehler, J., Blöchinger, A. K., Meier, M., & Lickert, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00262-w · Cited by 125
Autologous Pluripotent Stem Cell–Derived β-Like Cells for Diabetes Cellular Therapy
Millman, J. R., & Pagliuca, F. W. (2017) · Diabetes · doi:10.2337/db16-1406 · Cited by 99
Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes
Markmann, J. F., Rickels, M. R., Eggerman, T. L., Bridges, N. D., Lafontant, D. E., Qidwai, J., Foster, E., Clarke, W. R., Kamoun, M., Alejandro, R., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16174 · Cited by 111
Self-citationWhy should people with type 1 diabetes exercise regularly?
Codella, R., Terruzzi, I., & Luzi, L. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0978-x · Cited by 120
“IT restores glycemic control awareness and offers protection against severe hypoglycemia, at least in the mid-term after transplant [77].”
BackgroundWang, X., Maxwell, K. G., Wang, K., Bowers, D. T., Flanders, J. A., Liu, W., Wang, L.-H., Liu, Q., Liu, C., Naji, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4601 · Cited by 119
Self-citationYu, M., Agarwal, D., Korutla, L., May, C. L., Wang, W., Griffith, N. N., Hering, B. J., Kaestner, K. H., Velazquez, O. C., Markmann, J. F., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0269-7 · Cited by 110
Self-citationZhan, L., Rao, J. S., Sethia, N., Slama, M. Q., Han, Z., Tobolt, D., Etheridge, M., Peterson, Q. P., Dutcher, C. S., Bischof, J. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01718-1 · Cited by 115
Applications of iPSC-derived beta cells from patients with diabetes
Maxwell, K. G., & Millman, J. R. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100238 · Cited by 113
Hu, X., Gattis, C., Olroyd, A. G., Friera, A. M., White, K., Young, C., Basco, R., Lamba, M., Wells, F., Ankala, R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg5794 · Cited by 99
Rickels, M. R., Stock, P. G., de Koning, E. J. P., Piemonti, L., Pratschke, J., Alejandro, R., Bellin, M. D., Berney, T., Choudhary, P., Johnson, P. R., et al. (2018) · Transplant International · doi:10.1111/tri.13138 · Cited by 97
“With the International Hypoglycemia Study Group providing further consensus on definitions of hypoglycemia for clinical trials,(5) the evaluation of hypoglycemia in addition to some average metric of glycemic control, such as HbA1c, will be necessary for the selection of patients for and assessment of all forms of β-c…”
Self-citationSilva, I. B. B., Kimura, C. H., Colantoni, V. P., & Sogayar, M. C. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02977-y · Cited by 106
“[13], transplantation of pancreatic islets is a safe and efficient treatment option for T1D patients with hypoglycemia.”
BackgroundYale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Self-citationVantyghem, M.-C., Chetboun, M., Gmyr, V., Jannin, A., Espiard, S., Le Mapihan, K., Raverdy, V., Delalleau, N., Machuron, F., Hubert, T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0401 · Cited by 105
Rickels, M. R., Stock, P. G., de Koning, E. J. P., Piemonti, L., Pratschke, J., Alejandro, R., Bellin, M. D., Berney, T., Choudhary, P., Johnson, P., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002158 · Cited by 104
Self-citationRegenerative medicine and cell-based approaches to restore pancreatic function
Ellis, C. E., Ramzy, A., & Kieffer, T. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.93 · Cited by 98
The Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 97
Conformal Coating of Stem Cell-Derived Islets for β Cell Replacement in Type 1 Diabetes
Stock, A. A., Manzoli, V., De Toni, T., Abreu, M. M., Poh, Y.-C., Ye, L., Roose, A., Pagliuca, F. W., Thanos, C., Ricordi, C., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.11.004 · Cited by 96
“The islet transplantation field has grown tremendously in the past decades (Hering et al., 2016).”
BackgroundSelf-citationOxygenation strategies for encapsulated islet and beta cell transplants
Papas, K. K., De Leon, H., Suszynski, T. M., & Johnson, R. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.002 · Cited by 84
The Future of Islet Transplantation Is Now
Bottino, R., Knoll, M. F., Knoll, C. A., Bertera, S., & Trucco, M. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00202 · Cited by 93
“However, until further development of effective and less harmful immunosuppression, it was recommended only for the 20–30% of patients with T1D who suffer from SHEs despite exhausting all less invasive approaches of treatment (42).”
BackgroundLin, Y. K., Hung, M., Sharma, A., Chan, O., Varner, M. W., Staskus, G., & Fisher, S. J. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0527 · Cited by 81
“For patients with IAH and recurrent severe hypoglycemia, pancreas or islet transplantation can be considered as potential treatment options (7,8).”
BackgroundStem-cell based organ-on-a-chip models for diabetes research
Rogal, J., Zbinden, A., Schenke‐Layland, K., & Loskill, P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.010 · Cited by 93
Clinical islet transplantation: is the future finally now?
Pepper, A. R., Bruni, A. D. C., & Shapiro, A. M. J. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000546 · Cited by 85
Self-citationFukuda, Y., Akagi, T., Asaoka, T., Eguchi, H., Sasaki, K., Iwagami, Y., Yamada, D., Noda, T., Kawamoto, K., Gotoh, K., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.020 · Cited by 84
Advances in Encapsulation and Delivery Strategies for Islet Transplantation
Wu, S., Wang, L., Fang, Y., Huang, H. W., You, X., & Wu, J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100965 · Cited by 84
Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies
Bellin, M. D., & Dunn, T. B. (2020) · Diabetologia · doi:10.1007/s00125-020-05184-7 · Cited by 81
Self-citationBuchwald, P., Tamayo‐Garcia, A., Manzoli, V., Tomei, A. A., & Stabler, C. L. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26442 · Cited by 73
“…insulin independence with proven safety and efficacy, and it is likely to become an approved clinical treatment in T1D patients complicated by severe hypoglycemia (Fiorina, Shapiro, Ricordi, & Secchi, 2008; Hering et al., 2016; Ricordi & Strom, 2004; Shapiro, Pokrywczynska, & Ricordi, 2017).”
BackgroundCurrent state and future evolution of pancreatic islet transplantation
Anazawa, T., Okajima, H., Masui, T., & Uemoto, S. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12214 · Cited by 77
FasL microgels induce immune acceptance of islet allografts in nonhuman primates
Lei, J., Coronel, M. M., Yolcu, E. S., Deng, H., Grimany-Nuno, O., Hunckler, M. D., Ulker, V., Yang, Z., Lee, K. M., Zhang, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9881 · Cited by 77
Self-citationAlcazar, O., & Buchwald, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00680 · Cited by 77
“8 → G28 step is used for clinical (transplantation) assessment (50, 51) as well as for islet”
MethodRefat, M. S. E.-D., Hamza, R. Z., Adam, A. M. A., Saad, H. A., Gobouri, A. A., Al-Harbi, F. S., Al‐Salmi, F. A., Altalhi, T., & El‐Megharbel, S. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246265 · Cited by 77
“Zn is a vital element involved in the formation of β-cells of islet of Langerhans, and Zn deficiency correlates with the development of diabetes mellitus and glycemic complications [54].”
BackgroundPancreatic islet transplantation: current advances and challenges
Wang, Q., Huang, Y., Liu, L., Zhao, X., Sun, Y., Mao, X., & Li, S.-W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1391504 · Cited by 76
Shin, J., Kim, J. M., Min, B., Yoon, I. H., Kim, H. J., Kim, J., Kim, Y., Kang, S., Kim, J., Kang, H. J., et al. (2017) · Xenotransplantation · doi:10.1111/xen.12356 · Cited by 76
Salg, G. A., Giese, N. A., Schenk, M., Hüttner, F. J., Felix, K., Probst, P., Diener, M. K., Hackert, T., & Kenngott, H. (2019) · Journal of Tissue Engineering · doi:10.1177/2041731419884708 · Cited by 76
Gamble, A., Pawlick, R. L., Pepper, A. R., Bruni, A. D. C., Adesida, A. B., Senior, P. A., Korbutt, G. S., & Shapiro, A. M. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206449 · Cited by 75
Self-citationPig-to-Primate Islet Xenotransplantation: Past, Present, and Future
Liu, Z., Hu, W., He, T., Dai, Y., Hara, H., Bottino, R., Cooper, D. K. C., Cai, Z., & Mou, L. (2017) · Cell Transplantation · doi:10.3727/096368917x694859 · Cited by 74
Hu, X., White, K., Young, C., Olroyd, A. G., Kievit, P., Connolly, A. J., Deuse, T., & Schrepfer, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.02.001 · Cited by 73
Anwar, I. J., Berman, D. M., DeLaura, I. F., Gao, Q., Willman, M. A., Miller, A., Gill, A., Gill, C., Perrin, S., Ricordi, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6376 · Cited by 70
Self-citationTargeted demethylation at the CDKN1C/p57 locus induces human β cell replication
Ou, K., Yu, M., Moss, N., Wang, Y. J., Wang, A. W., Nguyen, S. C., Jiang, C., Feleke, E., Kameswaran, V., Joyce, E. F., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99170 · Cited by 70
Self-citationWojtusciszyn, A., Branchereau, J., Esposito, L., Badet, L., Buron, F., Chetboun, M., Kessler, L., Morelon, E., Berney, T., Pattou, F., et al. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.006 · Cited by 54
Bio-Engineering of Pre-Vascularized Islet Organoids for the Treatment of Type 1 Diabetes
Wassmer, C.-H., Lebreton, F., Bellofatto, K., Perez, L., Cottet-Dumoulin, D., Andres, A., Bosco, D., Berney, T., Othenin-Girard, V., Martinez De Tejada, B., et al. (2022) · Transplant International · doi:10.3389/ti.2021.10214 · Cited by 61
“Most importantly, pancreatic islet transplantation confers a significant improvement in glycemic control and prevents life-threatening severe hypoglycaemia (2).”
BackgroundChetboun, M., Drumez, E., Ballou, C., Maanaoui, M., Payne, E., Barton, F., Kerr-Conte, J., Vantyghem, M.-C., Piemonti, L., Rickels, M. R., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00082-7 · Cited by 64
Self-citationRickels, M. R., Eggerman, T. L., Bayman, L., Qidwai, J. C., Alejandro, R., Bridges, N. D., Hering, B. J., Markmann, J. F., Senior, P. A., Hunsicker, L. G., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2688 · Cited by 54
Self-citationRickels, M. R., Peleckis, A. J., Markmann, E., Dalton-Bakes, C., Kong, S. M., Teff, K. L., & Naji, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1649 · Cited by 60
Self-citationArroyave, F., Montaño, D., & Lizcano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228685 · Cited by 62
“Pig pancreatic islets can be adequately applied for clinical use in humans, avoiding some of the technical limitations involved in cadaveric transplants, such as senescence, brain death, comorbidities, or cold ischemia [130,131].”
BackgroundLenguito, G., Chaimov, D., Weitz, J. R., Rodriguez-Diaz, R., Rawal, S. A. K., Tamayo-Garcia, A., Caicedo, A., Stabler, C. L., Buchwald, P., & Agarwal, A. (2017) · Lab on a Chip · doi:10.1039/c6lc01504b · Cited by 58
Wang, X., Brown, N. K., Wang, B., Shariati, K., Wang, K., Fuchs, S., Melero‐Martin, J. M., & Ma, M. (2021) · Advanced Science · doi:10.1002/advs.202003708 · Cited by 62
García-Contreras, M., Tamayo, A., Pappan, K. L., Michelotti, G. A., Stabler, C. L., Ricordi, C., & Buchwald, P. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00160 · Cited by 61
Self-citation(Re)generating Human Beta Cells: Status, Pitfalls, and Perspectives
Baeyens, L., Lemper, M., Staels, W., Groef, S. D., Leu, N. D., Heremans, Y., German, M. S., & Heimberg, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2016 · Cited by 62
Youngblood, R. L., Sampson, J. P., Lebioda, K. R., Spicer, G. L. C., & Shea, L. D. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.032 · Cited by 62
Lablanche, S., Borot, S., Wojtusciszyn, A., Skaare, K., Penfornis, A., Malvezzi, P., Badet, L., Thivolet, C., Morelon, E., Buron, F., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16637 · Cited by 50
Advances in Cell Replacement Therapies for Diabetes
Hering, B. J., Rickels, M. R., Bellin, M. D., Millman, J. R., Tomei, A. A., García, A. J., Shirwan, H., Stabler, C. L., Ma, M., Peng, Y., et al. (2025) · Diabetes · doi:10.2337/db25-0037 · Cited by 61
Self-citationHuman Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges
Wang, P., Karaköse, E., Choleva, L., Kumar, K., DeVita, R. J., García-Ocaña, A., & Stewart, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671946 · Cited by 60
Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia
Maker, A. V., Sheikh, R., & Bhagia, V. (2017) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-017-1603-8 · Cited by 59
Clinical islet transplantation: Current progress and new frontiers
Marfil‐Garza, B. A., Shapiro, A. M. J., & Kin, T. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.891 · Cited by 59
Self-citationXu, B., Fan, D., Zhao, Y., Li, J., Wang, Z., Wang, J., Wang, X., Guan, Z., & Niu, B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01576 · Cited by 58
Localized immune tolerance from FasL-functionalized PLG scaffolds
Skoumal, M., Woodward, K. B., Zhao, H., Wang, F., Yolcu, E. S., Pearson, R. M., Hughes, K. R., García, A. J., Shea, L. D., & Shirwan, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.015 · Cited by 49
Carnosine protects pancreatic beta cells and islets against oxidative stress damage
Miceli, V., Pampalone, M., Frazziano, G., Grasso, G., Rizzarelli, E., Ricordi, C., Casu, A., Iannolo, G., & Conaldi, P. G. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.02.016 · Cited by 55
Self-citationGiraldo, J. A., Molano, R. D., Rengifo, H. R., Fotino, C., Gattás‐Asfura, K. M., Pileggi, A., & Stabler, C. L. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.060 · Cited by 54
Beta‐cell replacement strategies for diabetes
Kieffer, T. J., Woltjen, K., Osafune, K., Yabe, D., & Inagaki, N. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12758 · Cited by 54
Tran, R., Moraes, C., & Hoesli, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-57787-0 · Cited by 53
Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes
Primavera, R., Kevadiya, B. D., Swaminathan, G., Wilson, R. J., Pascale, A. D., Decuzzi, P., & Thakor, A. S. (2020) · Nanomaterials · doi:10.3390/nano10040789 · Cited by 53
Maffi, P., Lundgren, T., Tufveson, G., Rafael, E., Shaw, J., Liew, A., Saudek, F., Witkowski, P., Gołąb, K., Bertuzzi, F., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1480 · Cited by 52
Self-citation
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.